Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...
MedPage Today on MSN

First complement inhibitor wins full approval in IgA nephropathy

Iptacopan significantly slowed kidney decline in a phase III trial ...

Complement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight

The treatment landscape for C3G has historically depended on the off-label use of multiple prescription therapies, ...
Nasdaq

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy is an advanced form of dry age-related macular degeneration, that ...
Medical News Today

What are the treatment options for C3G?

Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity. C3G ...

Novartis Pharma AG: Novartis Fabhalta (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...